Viking Malt is Introducing Barbin - The First E-platform for Grain Trade in Finland
Viking Malt, together with Cinia Solutions Oy and their German ERP supplier Point Informationsverarbeitung und Consulting GmbH, have built the first e-platform for grain trade in Finland. The platform is called Barbin and it will be taken into use gradually from the first of September to improve communication and automize the grain trade activities between farmers and Viking Malt. With the Barbin e-platform, grain growing contracts and price fixations for current and coming crop years can be made electronically. The system also functions as a communication channel and transmits information on analysis results, intake planning and delivered volumes between grain purchasing and the contract farmers. The contract confirmations and grain price offers are directly sent to farmers’ mobile phones. Through the introduction of these modern communication tools, Viking Malt streamlines the information flow with their contract farmers and becomes a forerunner of modern grain trade practices in Finland. The next step will be to introduce Barbin into the other Viking Malt countries. By digitalization of grain trade practices, Viking Malt aims to improve the efficiency of the Finnish malting barley supply chain and to be the most reliable and agile partner for the malting barley farmers also in the future.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170830005055/en/
Viking Malt is Introducing Barbin - The First E-platform for Grain Trade in Finland. In the picture on the left: Sanna Kivelä, Sourcing Manager, Viking Malt. (Photo: Business Wire)
Viking Malt
Viking Malt is the leading supplier of malt to breweries in Northern Europe and one of the global market leader in supplying special malts to breweries and distilleries. Viking Malt is a Finnish private company, owned by Polttimo Oy (62,5%) and Lantmännen ek för (37,5 %), with headquarters in Lahti and operations in Finland, Sweden, Denmark, Poland and Lithuania. The turnover is around 220 MEUR and number of personnel is 250.
Viking Malt home market is the Baltic Sea area, but having a strong foothold in the export market outside Europe, such as Asia, Latin America and Africa.
Cinia Group
Cinia Group makes the world smaller, smarter, and more secure with intelligent network, cloud, and software services. Strong expertise in mission-critical solution development is built on an uncompromised focus on robustness and reliability. Cyber security of ICT infrastructure is ensured by Cinia's advanced cloud based operating environment that meets the needs of most demanding organizations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170830005055/en/
Contact information
Viking Malt Oy
Sanna Kivelä
Sourcing Manager
sanna.kivela@vikingmalt.com
+358
447391722
or
Cinia Solutions Oy
Petri Mähönen
Business
Director, Software services
petri.mahonen@cinia.fi
+358
405956563
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom